Correlation Between Equillium and ESSA Pharma
Can any of the company-specific risk be diversified away by investing in both Equillium and ESSA Pharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Equillium and ESSA Pharma into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Equillium and ESSA Pharma, you can compare the effects of market volatilities on Equillium and ESSA Pharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Equillium with a short position of ESSA Pharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Equillium and ESSA Pharma.
Diversification Opportunities for Equillium and ESSA Pharma
0.57 | Correlation Coefficient |
Very weak diversification
The 3 months correlation between Equillium and ESSA is 0.57. Overlapping area represents the amount of risk that can be diversified away by holding Equillium and ESSA Pharma in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on ESSA Pharma and Equillium is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Equillium are associated (or correlated) with ESSA Pharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of ESSA Pharma has no effect on the direction of Equillium i.e., Equillium and ESSA Pharma go up and down completely randomly.
Pair Corralation between Equillium and ESSA Pharma
Allowing for the 90-day total investment horizon Equillium is expected to generate 0.76 times more return on investment than ESSA Pharma. However, Equillium is 1.31 times less risky than ESSA Pharma. It trades about 0.0 of its potential returns per unit of risk. ESSA Pharma is currently generating about -0.12 per unit of risk. If you would invest 87.00 in Equillium on September 13, 2024 and sell it today you would lose (17.00) from holding Equillium or give up 19.54% of portfolio value over 90 days.
Time Period | 3 Months [change] |
Direction | Moves Together |
Strength | Weak |
Accuracy | 100.0% |
Values | Daily Returns |
Equillium vs. ESSA Pharma
Performance |
Timeline |
Equillium |
ESSA Pharma |
Equillium and ESSA Pharma Volatility Contrast
Predicted Return Density |
Returns |
Pair Trading with Equillium and ESSA Pharma
The main advantage of trading using opposite Equillium and ESSA Pharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Equillium position performs unexpectedly, ESSA Pharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ESSA Pharma will offset losses from the drop in ESSA Pharma's long position.Equillium vs. Lyra Therapeutics | Equillium vs. Hookipa Pharma | Equillium vs. Jasper Therapeutics | Equillium vs. Cingulate Warrants |
ESSA Pharma vs. Altamira Therapeutics | ESSA Pharma vs. Summit Therapeutics PLC | ESSA Pharma vs. Avenue Therapeutics | ESSA Pharma vs. Spero Therapeutics |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Other Complementary Tools
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device |